Biocryst Pharma Inc (BCRX) 3.71 $BCRX BioCryst

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 3:16 PM

Biocryst Pharma Inc (BCRX) 3.71 $BCRX

BioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 13.7%
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:25AM CDT
BioCryst Pharmaceuticals, Inc. (BCRX) moved big last session, as its shares jumped almost 14% on the day.
BCRX: 3.71 (+0.09)

BioCryst to Present at Two Upcoming Investor Conferences
GlobeNewswire - Thu May 26, 7:55AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the following investor conferences:
BCRX: 3.71 (+0.09)

BioCryst Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 5:44AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2016.
BCRX: 3.71 (+0.09)

BioCryst to Announce First Quarter 2016 Financial Results May 5
GlobeNewswire - Thu Apr 21, 5:48AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2016 financial results will be released on Thursday, May 5, 2016. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Thomas R. Staab, II, Senior Vice President and Chief Financial Officer and Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer.
BCRX: 3.71 (+0.09)

BioCryst to Present at Barclays Healthcare Conference
GlobeNewswire - Wed Mar 09, 8:29AM CST
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's development programs at the Barclays Healthcare Conference in Miami, FL on Thursday, March 17, 2016 at 1:05 pm. Eastern Time.
BCRX: 3.71 (+0.09)

BioCryst Pharmaceuticals (BCRX) Jumps: Stock Up 15.5%
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 7:15AM CST
BioCryst Pharmaceuticals, Inc. (BCRX) shares rose almost 16% in the last trading session.
BCRX: 3.71 (+0.09), EARS: 4.17 (+0.16)

Traders Get Bullish on Shares of BioCryst Pharmaceuticals, Shares Up 18.8% (BCRX)
Comtex SmarTrend(R) - Mon Mar 07, 10:18AM CST
BioCryst Pharmaceuticals (NASDAQ:BCRX) is one of today's best performing low-priced stocks, up 18.8% to $3.07 on 1.5x average daily volume. BioCryst Pharmaceuticals has traded 2.8 million shares thus far today, vs. average volume of 1.9 million shares per day. The stock has outperformed the Dow (18.8% to the Dow's 0.1%) and outperformed the S&P 500 (18.8% to the S&P's -0.2%) during today's trading.
BCRX: 3.71 (+0.09)

Study Results From Zika Virus Infected Mice Treated With BCX4430 to be Presented at WHO Conference
GlobeNewswire - Mon Mar 07, 5:45AM CST
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that results from a preclinical study of its broad spectrum antiviral BCX4430 in immune-deficient mice infected with Zika virus will be presented at a World Health Organization (WHO) meeting scheduled to take place March 7-9 in Geneva, Switzerland.
BCRX: 3.71 (+0.09)

Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma
Arpita Dutt - Zacks Investment Research - Wed Feb 10, 10:02AM CST
Disappointing pipeline and regulatory updates from companies like CTI BioPharma (CTIC) and Sarepta (SRPT) and earnings misses from Alexion and Regeneron were the highlights this week.
BCRX: 3.71 (+0.09), VRTX: 98.26 (+1.26), GILD: 80.48 (+1.01), SRPT: 25.78 (+0.50), ALXN: 133.26 (+4.66), CTIC: 0.33 (-0.01), REGN: 435.33 (+10.21)

BioCryst Pharmaceuticals (BCRX) in Focus: Stock Jumps 6.2%
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:35AM CST
BioCryst Pharmaceuticals, Inc. (BCRX) was a big mover last session, as the company saw its shares rise over 6% on the day.
BCRX: 3.71 (+0.09), PETX: 7.43 (-0.16)

Company News for February 09, 2016
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 9:10AM CST
Companies in the News are; HAS,DO,CNA,BCRX
HAS: 81.31 (+0.08), BCRX: 3.71 (+0.09), DO: 21.13 (-1.59), CNA: 31.43 (-0.40)

Downgrade Alert for BioCryst Pharmaceuticals (BCRX)
Comtex SmarTrend(R) - Tue Feb 09, 8:11AM CST
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded from Buy to Hold at Jefferies today. The stock closed yesterday at $1.78 on volume of 9.3 million shares, above average daily volume of 761,000. BioCryst Pharmaceuticals (NASDAQ:BCRX) has potential upside of 812.9% based on a current price of $1.78 and analysts' consensus price target of $16.25. The stock should find initial resistance at its 50-day moving average (MA) of $8.86 and further resistance at its 200-day MA of $11.16.
BCRX: 3.71 (+0.09)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of BioCryst Pharmaceuticals, Inc. -- BCRX
BusinessWire - Mon Feb 08, 11:04AM CST
Levi & Korsinsky announces it has commenced an investigation of BioCryst Pharmaceuticals, Inc. (NASDAQGS: BCRX) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
BCRX: 3.71 (+0.09)

Shares of BCRX Down 20.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 05, 10:49AM CST
SmarTrend identified a Downtrend for BioCryst Pharmaceuticals (NASDAQ:BCRX) on January 11th, 2016 at $8.23. In approximately 4 weeks, BioCryst Pharmaceuticals has returned 20.91% as of today's recent price of $6.51.
BCRX: 3.71 (+0.09)

WHO Declares Zika A Health Emergency of International Concern: 5 Companies Developing Technologies in the Fight against the Epidemic
ACCESSWIRE - Wed Feb 03, 8:22AM CST
WINDSOR, ON / ACCESSWIRE / February 3, 2016 / The Wealthy Biotech Trader (or "WBT"

, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, has researched several stocks on the front lines in the fight against Zika, an epidemic spreading from South America that causes flu-like symptoms but is feared to cause horrible birth defects in babies whose mothers become infected.
INO: 10.46 (+0.58), BCRX: 3.71 (+0.09), CMRX: 4.10 (+0.11), XON: 27.38 (+2.05)

16.4% Return Seen to Date on SmarTrend BioCryst Pharmaceuticals Call (BCRX)
Comtex SmarTrend(R) - Fri Jan 29, 10:19AM CST
SmarTrend identified a Downtrend for BioCryst Pharmaceuticals (NASDAQ:BCRX) on January 11th, 2016 at $8.23. In approximately 3 weeks, BioCryst Pharmaceuticals has returned 16.40% as of today's recent price of $6.88.
BCRX: 3.71 (+0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Truss Financial Tackles Home Equity Closing Delays

Truss Financial Group's Bold Move Against Closing Delays In real estate, time is money. Even the most casual market observer could tell you delays can slice through a deal like a hot knife through butter. That's the headache home equity borrowers face, blindsided by closing delays that sneak up on them without warning. An Industry Bottleneck Finally Addressed Enter Truss...

Community Banks Missing $106B Lending Opportunity?

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

Dentistry.One Achieves HITRUST i1, Boosts Cybertrust

HITRUST i1 Certification: The Gold Standard in Security For a world increasingly reliant on digital infrastructure, cybersecurity certification is no longer just a badge of honor; it's a cornerstone of trust. Dentistry.One nailed this down by bagging that coveted HITRUST i1 certification. When folks talk about securing data, HITRUST might as well be speaking gospel. We're...

Charter Next Generation Unveils Gen 2 MDO-PE Films

Peering Into CNG's Latest Innovation Charter Next Generation (CNG) just threw down a hefty gauntlet with its launch of next-gen machine-direction-oriented polyethylene (MDO-PE) solutions. They're pushing the envelope on what recycle-ready packaging can do, folks. Let's not mince words—other players in the field better have their game faces on. This ain't just another...

Cala Launches Game-Changer Wearable for Tremor Relief

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...

Epic Political Thriller Explores Humanity's Future

Adams' Provocative Debut Asks Timeless Questions Sometimes life throws a philosophical curveball, and that's exactly what John C. Adams has done with his debut novel, The Third Phase. This isn't your average political yarn—it's an intricate tapestry intertwining political intrigue, deep spiritual inquiry, and hearty doses of classic philosophy. A Whirlwind Journey...

ROKFORM’s Signal Card: A Wallet Tracker for All

The Gadget You Didn't Know You Needed Ever feel that momentary panic when your wallet seems to have vanished into thin air? ROKFORM's fresh offering, the Signal Card, tackles that heart-stopping moment head-on. They've taken the mundane act of misplacing your wallet and transformed it with their sleek, credit-card-sized tracker. This baby pairs seamlessly with Apple Find...

Navigating Holiday Sweets: Healthy Balancing Acts

In the middle of the sweet madness that is the holiday season, Crispy Green and Dr. Nicole Avena are playing guide to families drowning in sugar. This isn't just a once-a-year Halloween headache; we're starting that sugar spiral early and letting it ride until the New Year approaches. It's an all-hands-on-deck situation if families want to dodge that sugar overload. Why...

Cure Blindness Project's 770K Screenings for World Sight Day

Visionary Steps Toward a Brighter Future No two words could describe the task that Cure Blindness Project is tackling this year: vision and action. Marking World Sight Day on October 8, they plan to usher in 770,000 eye screenings across Asia, Africa, and the Caribbean. These initiatives aren't just numbers—they're a colossal step toward lifting the veil of avoidable...

NYSE Texas Redefines the U.S. Capital Markets Landscape

NYSE Texas: Carving a Niche The notion of 'Y'all Street' might seem like a gimmick, but NYSE Texas is pushing a serious agenda with its newly released white paper, 'NYSE Texas and the Reshaping of U.S. Capital Markets.' This is no small feat. Texas is already housing 235 NYSE-listed companies, boasting a colossal combined worth of $4.8 trillion. With 130 of these firms...